Lung Cancer Trial, Recruiting NCT06648317 Sponsor: Peking University Cancer Hospital & Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06648317
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old, of any gender
  • People with normal heart function
  • People whose doctors estimate they are likely to survive for at least 12 weeks
  • People who are willing and able to attend follow-up appointments as required
  • People who have at least one measurable area of disease that can be tracked according to standard imaging guidelines (known as RECIST 1.1)
  • Women of childbearing age (15–49 years) for whom a pregnancy test taken within 7 days before the trial starts comes back negative
  • People who are able to use effective contraception during the trial and for 3 months after it ends (applies to both men and women who could father or become pregnant)
  • People whose doctor has recommended a PET/CT scan for cancer diagnosis or staging
  • People who fully understand the trial and have signed a consent form agreeing to take part voluntarily

Who may not be able to join:

  • People with serious problems affecting the liver, kidneys, or blood
  • People who are currently pregnant or breastfeeding
  • People who are unable to lie still and flat for approximately 30 minutes
  • People who do not wish to participate in the trial
  • People who experience claustrophobia or have certain other mental health conditions
  • People whose doctors consider them unsuitable for the trial for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nan Li, MD, Peking University Cnacer Hospital & Institute

Phone: +86-13693090647

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
21 November 2024
Est. completion
1 March 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Standardized uptake value(SUV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov